SACRAMENTO, Calif., May 30, 2019 /PRNewswire/ -- International life sciences corporation, Anpac Bio-Medical Science Company (Anpac Bio) Chief Executive Officer Dr. Chris Yu, announced today the company is presenting "unprecedented" cerebral cancer research results at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, May 31 – June 4, 2019.
Anpac Bio is exhibiting in a Poster Session (Board #229) on Sunday, June 2, 2019, 8:00 am – 11:00 am, in ASCO Annual Meeting Hall A; and publishing on the ASCO Meeting Abstract web page, (Citation: J Clin Oncol 37, 2019 suppl; abstract 2040), "Cancer differentiation analysis technology as a novel technology for cerebral cancer screening". In both the poster session and Abstract, Anpac Bio reveals the results of its proprietary "Cancer Differentiation Analysis" (CDA) liquid biopsy technology screening of blinded cerebral cancer, and healthy, control, blood samples - indicating CDA effectively distinguished the cerebral cancer samples with 92% sensitivity and 96% specificity.
The Abstract's conclusion: "Initial results showed that CDA technology could effectively distinguish cerebral cancer from healthy individuals. As a novel bio-physical based cancer detection approach with multi-level and multi-parameter expressions, CDA could be a potential candidate for cerebral cancer screening."
ASCO also published/posted Anpac Bio's Non-Small Cell Lung Cancer (NSCLC) early detection screening research study Abstract, (Citation: J Clin Oncol 37, 2019 suppl; abstr e20673), "A novel biophysical based marker with multilevel, multiparameter expression for early stage cancer detection". The Abstract outlines research results demonstrating CDA identified Stage I NSCLC with significant accuracy - achieving 85% sensitivity and 93% specificity.
"Our Anpac Bio R&D team is proud to present our truly breakthrough, CDA liquid biopsy cancer screening results at ASCO," states Yu. "We particularly look forward to sharing at our poster session our unprecedented, cerebral cancer research results, that demonstrate CDA identifies cerebral cancer with over 90% sensitivity and specificity, from simple, standard blood samples."
Anpac Bio's comprehensive research validity data from 100,000+ cases demonstrate CDA consistently detects 20+ cancer types, with 80%-95% sensitivity and specificity rates -- usually at the diseases' earliest stages. And it does so without harmful patient side effects; generating far fewer "false positives"; and at a cost substantially lower than traditional testing. Anpac Bio has filed 200+ CDA-related patent applications worldwide – 100+ issued in 20 countries and regions (to date).
For further information: www.AnpacBio.com.
SOURCE Anpac Bio-Medical Science Company
Share this article